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This distribution consists of 300 ng aliquots of plasmid DNA for each of twelve components and
compound constructs utilizing our idempotent assembly strategy. The dried DNA should be stable
at room temperature for many weeks, but long term storage at -20 or -80 in the resealable foil pouch
with desiccant is recommended. This document and much additional information, protocols, and
detailed sequences is or will be available from the site http://ks.ai.mit.edu
Well number 1 is marked with a red marker. The foil top can be pierced with a pipet tip to add DI
water for resuspending the sample. We recommend resuspending in 100 µl water, and transfering
the resuspended sample to another labelled tube for more permanent storage. Standard heat shock
or electroporation transformation techniques can be used to introduce the plasmid into E. coli cell
lines. Samples were dried down from 10 µl of TE 10:0.1, so the solution will contain small amounts of
Tris and EDTA. For electroporation, it might be necessary to further dilute or dialyze the samples to
avoid arcing. Our standard strain for cloning is the Invitrogen library efficiency chemically competent
DH5α strain, catalog number 18263-012. All constructs are based on a pUC18 backbone, and are
high copy number and ampicillin resistant. We grow strains in Difco LB Lennox broth or agar with
100 µg/l of ampicillin (Sigma A0166).
Expression of the lacZα gene can best be seen on Sigma S-gal plates, which provide a marked
improvement over X-gal plates.
Note that the DH5α strain does not express LacI. Controlled expression of LacI should be done with
a construct providing LacI or in a lacIq strain such as XL1-Blue.
Much of the power of these assembly techniques arise from a consistent, widely available set of
components. We strongly encourage others who develop components in this form to contact us with
complete information and samples, if possible. We volunteer to act as a community coordination
and distribution point for these components as they are developed. If you have components which
you believe are useful but not in this form, we may, in many cases, be interested in doing the work
necessary to cast them into standard component form.
We are working to develop licenses which would encourage widespread free distribution of DNA
components, sequences, and documentation and intend those licenses, as developed, to apply to
these components and assembly strategies.
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Standard Components and Assemblies, May, 2002 Distribution
1. pSB103
Base plasmid for the Biobrick idempotent assembly technique.
2. pSB103-Plac
Plasmid containing the Plac promoter. CAP and LacI repressor binding sites. Wild type
sequence.
3. pSB103-lacZα
Plasmid containing the lacZα coding sequence and an upstream ribosomal binding site. This
is the alpha complementation portion of the wild type gene, missing the multiple cloning site
introduced by Messing.
4. pSB103-ECFP
Plasmid containing the Clontech ECFP gene and an upstream ribosomal binding site.
5. pSB103-EYFP
Plasmid containing the Clontech EYFP gene and an upstream ribosomal binding site. A silent
mutation to eliminate the PstI cut site within the coding sequence has been introduced to
conform with standard biobrick assembly standards.
6. pSB103-T1
Plasmid containing the rrnB-T1 transcriptional terminator.
7. pSB103-Plac-ECFP
Plasmid expressing the ECFP gene from the Plac promoter.
8. pSB103-Plac-EYFP
Plasmid expressing the EYFP gene from the Plac promoter.
9. pSB103-Plac-ECFP-EYFP
Plasmid expressing both the ECFP and EYFP genes from the Plac promoter.
10. pSB103-Plac-EYFP-ECFP
Plasmid expressing both the EYFP and ECFP genes (opposite order) from the Plac promoter.
11. pSB103-Plac-ECFP-T1-EYFP
Plasmid expressing ECFP with dramatically reduced EYFP expression due to the T1 termi-
nator.
12. pSB103-Plac-EYFP-T1-ECFP
Plasmid expressing EYFP with dramatically reduced ECFP expression due to the T1 termi-
nator.
This work is supported by the DARPA/ONR contract “Computing with Synthetic Biology.”
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